Sponsored by Sica Media and Disseminated on Behalf of Actinium Phamaceuticals, Inc*

The markets are staging a potential comeback following a lackluster week. There’s a setup topping my radar right now that formed a base last week. With a catalyst out on Friday, I’m watching closely for a bottom-bounce today.

TODAY’S TOP ALERT! 

Actinium Pharmaceuticals (NYSE: ATNM)

👉  ATNM is TODAY’S #1 ALERT 👈

Good morning, Folks, and happy Monday. (If you’re a Bullseye member, look out for my trade plan email about 9:15am EST!)

Believe it or not, the Nasdaq actually managed to close down last week as investors cast some doubt on the AI trade. 

Still, the S&P 500 closed the week slightly up, and things are looking good in the futures market as I write this.

That mixed performance is a perfect setup for the start of the Santa Rally 🎅🏻.

As I always point out, and what most people don’t realize, is that that well-established market trend actually begins the week before Thanksgiving…

And looking at my calendar, it appears that week is upon us.

The big question mark will be NVDA earnings on Wednesday. If investors like what they see there, we could really be off to the races.

Right now, I’m turning to a “tactical trade” idea that treated us very well when I first alerted it last year…

By the day after my alert, the stock ripped as high as 30%. By the fifth day, it reached 50% higher.

Have a good look at Actinium Pharmaceuticals, Inc. (ATNM) on your trading platform.

The stock has been in a gradual downtrend since early September, apart from a big but brief bounce in October when it punched 17% higher in a single day.

But zoom in on the chart from the past week.

You can see that the stock has stabilized, and it could well be in oversold territory.

I’m watching the stock today to see if the $1.25–$1.33 level it’s at will act as a base for a rebound higher…

The stock is already jumping higher in pre-market activity today, gaining over 10% at one point.

The catalyst could be the 10-Q the company filed on Friday.

In it, ATNM noted that it had received a letter from pharma giant Novartis in August objecting to ATNM’s comparison of its candidate ATNM-400 with Novartis’ Pluvicto®, which generated sales of ~$1.4 billion in the first nine months of 2025.

ATNM found the letter “highly unusual” and defended its statements. ATNM’s research has found that ATNM-400 “demonstrated superior tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals” compared to the active ingredient in Pluvicto®.

It also demonstrated efficacy against tumors that developed resistance to that active ingredient.

The 10-Q also revealed that ATNM had more than $53 million in cash on its balance sheet as of September 30.

That’s huge for a pre-commercial pharma company like ATNM.

This could be just the catalyst ATNM needs to rebound from the base it has formed over the last week. That’s why 

👉  ATNM is TODAY’S #1 ALERT 👈

Actinium Pharmaceuticals, Inc. (ATNM) is a late-stage biopharmaceutical company developing targeted radiation treatments for cancer.

The company has a big portfolio of intellectual property, with more than 240 patents worldwide.

At the core of its strategy is a nuclear isotope called Actinium-225, which the company describes as “the most powerful medical grade radioisotope known to man.”

Critically, “its power is emitted over a short distance of a few millimeters making it ideal for targeted radiotherapy.”

The company’s therapies deploy this weapon directly to cancer cells using what it amusingly calls Antibody Warhead Enabling (AWE) technology. 

The idea is to target cancer cells specifically, like a heat-seeking missile, unlike prevailing radiation therapies which have a much more systemic impact.

This strategy has possible indications for many kinds of cancers, but ATNM put it fully to the test in a now-completed Phase III trial for older patients with relapsed or refractory acute myeloid leukemia (AML).

The results were incredible…

In the control arm of the trial, no patients survived beyond one year, despite receiving the usual treatments.

For the patients who received Iomab-B — one of the company’s proprietary radiopharmaceuticals, which has received an orphan drug designation — 20.1% survived one year, and 11.5% were alive after two years, a duration the company says is “highly indicative of long-term outcomes including potential cure.”

A two-year survival rate of 11.5% may not seem great, but this is a particularly nasty form of cancer, so this therapy has the potential to become the new standard of care in these patients.

While the trial met its primary endpoint and several secondary endpoints, the FDA determined the results were not sufficient for a Biologics License Application (BLA) because overall survival benefit needs a randomized head-to-head trial.

The company is now searching for a partner for the new trial.

In my view the success of Iomab-B thus far is best seen as a proof-of-concept for the company’s targeted radiotherapies…

And indeed, ATNM has a much broader product pipeline and says its therapies could apply to solid tumors in addition to blood cancers.

In March, for instance, the company initiated “the first clinical trial under its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Actimab-A.”

Also that month, it published results from a clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia in the journal Leukemia.

The trial found an 18.4 month median Overall Survival (OS) and “high rates of measurable residual disease negativity.”

Principal investigator Dr. Sameem Abedin said, “We are excited that the combination of Actimab-A and CLAG-M produced high response rates with deep remissions including high rates of MRD negativity, improving access to potentially curable BMT resulting in enhanced survival outcomes.”

And in April, the company revealed preclinical results for ATNM-400 at the American Association for Cancer Research (AACR) Annual Meeting.

The upshot, as mentioned above, was that “In vivo studies demonstrated that ATNM-400 is more efficacious than Pluvicto.”

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom Line: ATNM appears to have found support over the last week, and with its 10-Q filed Friday with some very interesting inclusions, this could be the catalyst it needs to bounce from that base.

Stay glued to ATNM today to see if that plays out!

To Your Success,